Long-Term Prognosis of Patients With Anti-N-Methyl-D-Aspartate Receptor Encephalitis Who Underwent Teratoma Removal: An Observational Study

Hesheng Zhang, Weixi Xiong, Xu Liu, Wenyu Liu, Dong Zhou* and Xintong Wu*

Objective: This study aimed to evaluate the clinical characteristics and long-term surgical outcomes of patients with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis with teratoma.

Methods: Patients who were admitted to West China Hospital from June 2012 to June 2019 and diagnosed with anti-NMDAR encephalitis were enrolled in the study. Medical records were reviewed prospectively to gather clinical characteristic data. Patients were followed up at long-term every 3 months.

Results: This study included 192 patients, among whom 21 (10.9%) were detected with having a teratoma. Patients included 20 women, with a mean age of 24.62 ± 7.61 years. Seizure and psychiatric symptoms were the most dominant symptoms in both groups, followed by memory deficits. Central hypoventilation (52.4 vs. 17%, p < 0.001) and decreased consciousness (71.4 vs. 31.3%, p = 0.002) were significantly more frequent in patients with teratoma than in those without. Moreover, the anti-NMDAR antibody titer was higher (p = 0.021) and the baseline modified Rankin scale score was lower (p = 0.004) in patients with teratoma than in those without. First-line immunotherapy was performed in 21 (100%) patients with teratoma and 167 (97.7%) patients without teratoma. All patients with teratoma had the tumor removed. During follow-up, two (9.5%) patients with teratoma and 11 (6.4%) patients without teratoma died, whereas 1 (4.8%) patient with teratoma and 37 (21.6%) patients without teratoma had relapses. Overall, 19 (90.5%) patients with teratoma and 151 (88.3%) patients without teratoma achieved favorable clinical outcomes at the final follow-up.

Conclusions: With early detection and removal of teratoma, most patients with anti-NMDAR encephalitis and teratoma achieved a favorable long-term prognosis.

Keywords: anti-NMDAR encephalitis, teratoma, surgery, prognosis, relapse
INTRODUCTION

Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is an autoimmune disease that is characterized by psychiatric symptoms, seizures, memory deficits, speech impairment, movement disorders, autonomic instability, central hypventilation, and decreased consciousness (1–3). The condition is primarily mediated by specific immunoglobulin G (IgG) antibodies against the NRI subunit of the NMDAR. Tumors (mainly teratomas) containing nerve tissues can induce the production of specific antibodies via molecular mimicry and have been identified as a trigger of anti-NMDAR encephalitis (3, 4). Previous studies have reported a prevalence of teratoma at 20.2–45% in patients with anti-NMDAR encephalitis (5, 6). Immunotherapy is the most crucial therapeutic method for anti-NMDAR encephalitis. For patients with a tumor, surgery is an important treatment strategy and is recommended to be performed as soon as possible (3). In this study, we explored the clinical characteristics and long-term prognoses of these patients, following a surgery.

METHODS

Study Design and Participants

The Outcome of anti-NMDAR Encephalitis Study in Western China (ONE-WC) study was registered with the WHO international clinical trial registry platform (registration number: ChiCTR1800019762) and is described in more detail in our previous publications (7–11). Patients were hospitalized patients recruited from the Neurology Department of West China Hospital from October 2011 to June 2019. Inclusion criteria were as follows: (1) rapid onset of at least one of eight major groups of symptoms (psychosis, memory deficits, speech disturbances, seizures, movement disorders, disturbance of consciousness, autonomic dysfunctions, and central hypventilation) (1); (2) positive for anti-NMDAR antibodies in the cerebrospinal fluid (CSF).

Exclusion criteria were as follows: (1) human immunodeficiency virus infection, meningitis, brain abscess, prior diseases, cerebral malaria, brain tumor, or diagnosis of a non-infectious central nervous system disease, such as acute demyelinating encephalomyelitis; (2) patients with laboratory evidence of infectious encephalitis; (3) patients diagnosed with epilepsy, cerebral trauma, and/or other nervous system diseases prior to the onset of encephalitis; (4) patients with other coexisting positive autoimmune or neurologic paraneoplastic antibodies, such as α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors-1 and−2, contactin-associated protein-2, leucine-rich glioma-inactivated protein-1, c-aminobutyric acid receptor B1/B2, anti-neuronal nuclear antibody (ANNA)-1, ANNA-2, and Purkinje-cell cytoplasmic autoantibody-1.

Clinical Management

A lumbar puncture was performed in suspected patients with rapid onset of neurological or psychiatric disorders. Samples were assessed using an indirect immunofluorescence assay for the detection of autoimmune neurologic paraneoplastic antibodies. Individuals with confirmed antibodies underwent chest and abdomen CT or abdomen and reproductive system ultrasound to search for potential tumors. Abnormalities were reported by radiologists and reviewed by relevant specialists (e.g., gynecologists for a pelvic mass in women).

Treatments were administered by senior neurologists of West China Hospital, Department of Neurology. Immunotherapies included first-line immunotherapy (intravenous immunoglobulin [IVIg], methylprednisolone, and plasma exchange) and second-line immunotherapies (rituximab, cyclophosphamide, azathioprine, mycophenolate mofetil, and tacrolimus). First-line immunotherapies were administered as follows: 4 g/kg IVIg was administered daily for 5 days as one turn; 1,000 mg intravenous methylprednisolone was administered daily for 3–5 days as one turn, then replaced by daily prednisone. Repeated intravenous immunotherapy was administered to patients with a poor response. Other interventions included anti-epileptic drugs, anti-psychotic drugs, sedative-hypnotic drugs, and other symptomatic/supportive treatments.

Patients with a suspected tumor were evaluated by a multi-disciplinary team to determine whether surgery was recommended and its timing. Operations were performed by surgeons of West China Hospital of West China Second University Hospital. Patients were discharged following a surgery or transferred to a neurological intensive care unit for post-surgical immunotherapy depending on their neurological symptoms. Pathological diagnoses were made, following a surgery.

Data Collection and Definition

Patients’ clinical characteristics during hospitalization were extracted from medical records and included epidemiologic data (sex and age), clinical data (date of onset, date of admission, and typical symptoms), biological data (CSF antibody titers, CSF cell count, glucose/protein/IgG synthesis rates, and IgG index), auxiliary examination (MRI/CT results, ultrasound results, electroencephalography [EEG] results), and clinical management data (treatment administered, date of immunotherapy, and date of surgery). All data were collected by clinicians using a standardized form. Follow-up visits were conducted by a clinician every 3 months from clinical onset over the telephone. Patients’ neurological and psychiatric sequelae were questioned, and patients who reported worsening or new onset of the eight major groups of symptoms were requested to attend the neurological clinic to evaluate the possibility of relapse and undergo further investigations if necessary.

Outcomes were assessed using the modified Rankin scale (mRS) (12). Evaluations were carried out face-to-face by neurologists during hospitalization and by patients’ or guardians’ responses over the telephone, following the discharge. Relapse was defined as a worsening or new onset of previous symptoms, occurring after at least 2 months of improvement or stabilization and was confirmed by antibodies detected in the CSF. Clinical improvement was defined as a decrease of 1 or more in mRS score (2). A long-term favorable outcome was defined as an mRS score ≤ 2 (2).
### Table 1: Clinical features of patients with and without teratoma.

|                               | Total, n (%) | With teratoma, n (%) | Without teratoma, n (%) | P-value   |
|-------------------------------|--------------|----------------------|-------------------------|-----------|
| Quantity                      | 192          | 21                   | 171                     | 0.009*    |
| Age, years (mean ± SD)        | 29.44 ± 13.01| 24.62 ± 7.61         | 30.03 ± 13.46           | < 0.001*  |
| Sex (female)                  | 107 (55.7)   | 20 (95.2)            | 87 (50.9)               | 0.829*    |
| Psychiatric symptoms          | 175 (91.1)   | 19 (90.5)            | 156 (91.2)              | 0.660*    |
| Seizure                       | 153 (79.7)   | 18 (85.7)            | 135 (78.9)              | 0.124*    |
| Speech impairment             | 47 (24.5)    | 8 (38.1)             | 39 (22.8)               | 0.441*    |
| Autonomic instability         | 92 (47.9)    | 13 (61.9)            | 79 (46.2)               | 0.174*    |
| Memory deficits               | 157 (81.8)   | 15 (71.4)            | 142 (83.0)              | 0.193*    |
| Decreased consciousness       | 77 (40.1)    | 15 (71.4)            | 62 (36.3)               | 0.002*    |
| Cognitive disorder            | 126 (65.6)   | 13 (61.9)            | 113 (66.1)              | 0.650*    |
| Central hypoventilation       | 40 (20.8)    | 11 (52.4)            | 29 (17.0)               | < 0.001*  |
| Baseline mRS score            | 4 (4.5)      | 5 (4.5)              | 4 (4.5)                 | 0.004+    |
| Abnormal MRI findings         | 74/181 (40.9)| 7/21 (33.3)          | 67/160 (41.9)           | 0.454*    |
| Abnormal EEG findings         | 141/170 (82.9)| 16/18 (88.9)       | 125/152 (88.2)          | 0.705*    |
| Antibody titer in cerebrospinal fluid |          |                      |                         |           |
| 1:1–1:10                      | 44           | 1                    | 43                      | 0.021+    |
| 1:10–1:100                    | 115          | 13                   | 102                     |           |
| 1:100–1:1000                  | 33           | 7                    | 26                      |           |

*Student’s t-test.

a chi-squared or Fisher’s exact tests.

Wilcoxon’s test.

---

### Statistical Analysis

For all statistical analyses, SPSS 20 (SPSS Inc., Chicago, IL, USA) was used. Quantitative statistics are reported as means ± SDs (normally distributed) or medians (interquartile ranges [IQR]). Student’s t-tests were performed for comparisons of continuous variables. Chi-squared tests or Fisher’s exact tests were performed for comparisons of categorical variables. Wilcoxon’s test was used to analyze rank variables. A two-tailed p < 0.05 was considered significant.

### Ethics

This study was approved by the West China Hospital of the Sichuan University Research Ethics Committee. Informed consent was obtained from all patients.

### RESULTS

#### Clinical Characteristics

A total of 192 patients were included in this study, among whom 107 (55.7%) were women. The mean age of patients was 29.44 ± 13.01 years (range 9–78 years, IQR 19–37 years). Furthermore, 21 (10.9%) patients had teratoma, among whom 19 (90.5%) had an ovarian teratoma and two (9.5%) had a mediastinal teratoma. The prevalence of teratoma in women with anti-NMDAR encephalitis was 18.7%. Pathologic subtypes included mature teratoma in 18 (85.7%) patients, immature teratoma in two (9.5%) patients, and mixed germ cell tumor in one (4.8%) patient. The demographic and clinical characteristics are shown in Table 1. Table 2 shows the clinical characteristic of the 21 patients with teratoma.

The mean age of the teratoma cohort was younger than that of patients without teratoma (24.62 vs. 30.03 years, p = 0.009). Psychiatric symptoms (91.1%), memory deficits (81.8%), and seizures (79.7%) were the most dominant symptoms. Central hypoventilation (52.4 vs. 17%, p < 0.001) and decreased consciousness (71.4 vs. 31.3%, p = 0.002) were significantly more frequent in patients with teratoma than in those without. Gynecological symptoms were rare, wherein only one patient complained of a prolonged intermenstrual period, which may be related to the teratoma. One patient had a medical history of teratoma removal, and relapsed teratoma was detected. Patients with teratoma tended to score lower on the mRS during the acute phase than did patients without teratoma (p = 0.004). Approximately one-third of patients showed abnormal MRI findings, and over 80% of patients showed abnormal EEG findings. CSF findings suggested higher antibody titer in patients with teratoma (p = 0.021).

#### In-Hospital Management

First-line immunotherapies were administered to all patients with teratoma and 167 (97.7%) patients without teratoma. Patients with teratoma tended to use more turns of first-line immunotherapies (p = 0.013). The use of second-line immunotherapies did not significantly differ between the two groups. Among the 21 patients with teratoma, 17 (90%) patients underwent surgery during the acute phase before clinical improvement, and one patient underwent surgery...
TABLE 2  Clinical features of patients with teratoma.

| No. | Sex | Age | Prodrome | Initial symptoms  | Baseline mRS score | Pathology                                      |
|-----|-----|-----|----------|------------------|-------------------|-----------------------------------------------|
| Case 1 | f   | 18  | headache | seizures | 5 | mediastinal mature teratoma                  |
| Case 2 | f   | 17  | fever    | seizures | 5 | ovarian mature teratoma                      |
| Case 3 | m   | 25  | headache/nausea | psychiatric symptoms | 5 | mediastinal mixed germ cell tumor (choriocarcinoma and teratoma) |
| Case 4 | f   | 19  | headache/fever | psychiatric symptoms | 5 | ovarian mature teratoma                      |
| Case 5 | f   | 22  | -        | psychiatric symptoms | 3 | ovarian mature teratoma                      |
| Case 6 | f   | 28  | -        | psychiatric symptoms | 5 | ovarian mature teratoma                      |
| Case 7 | f   | 31  | headache/fever | seizures | 5 | ovarian mature teratoma                      |
| Case 8 | f   | 35  | -        | psychiatric symptoms | 5 | ovarian immature teratoma (WHO III)          |
| Case 9 | f   | 40  | dizziness | psychiatric symptoms | 4 | ovarian mature teratoma                      |
| Case 10 | f   | 18  | headache/fever | seizures | 5 | ovarian mature teratoma                      |
| Case 11 | f   | 20  | headache | psychiatric symptoms | 5 | ovarian mature teratoma                      |
| Case 12 | f   | 20  | finger numbness | seizures | 5 | ovarian mature teratoma                      |
| Case 13 | f   | 22  | sleep disorder | psychiatric symptoms | 4 | ovarian mature teratoma                      |
| Case 14 | f   | 43  | -        | seizures | 4 | ovarian immature teratoma (WHO III)          |
| Case 15 | f   | 17  | sleep disorder | psychiatric symptoms | 4 | ovarian mature teratoma                      |
| Case 16 | f   | 29  | headache/fever | psychiatric symptoms | 5 | ovarian mature teratoma                      |
| Case 17 | f   | 16  | upper-respiratory-tract symptoms | psychiatric symptoms | 4 | ovarian mature teratoma                      |
| Case 18 | f   | 26  | -        | psychiatric symptoms | 3 | ovarian mature teratoma                      |
| Case 19 | f   | 26  | headache/fever | psychiatric symptoms | 5 | ovarian mature teratoma                      |
| Case 20 | f   | 19  | -        | seizures | 5 | ovarian mature teratoma                      |
| Case 21 | f   | 26  | -        | psychiatric symptoms | 5 | ovarian mature teratoma                      |

before immunotherapy was administered. Table 3 shows the management of teratoma patients.

Follow-Up and Outcome

The median follow-up period was 46 months (6–91 months). During the follow-up period, two (9.5%) patients with teratoma and 11 (6.4%) patients without teratoma died. Among the two patients with teratoma who died, one died because of pulmonary metastasis of the tumor (mixed germ cell tumor) and secondary respiratory failure, and the other died because of pancreatitis, pulmonary infection, septic shock, and multiple organ dysfunction syndromes. In total, 19 (90.5%) teratoma patients and 151 (88.3%) patients without teratoma achieved a favorable clinical outcome at the final follow-up. The clinical management and outcomes of patients are shown in Table 4.

During the follow-up period, 39 patients experienced 47 relapses. Only one (4.8%) patient with teratoma relapsed at 7 months after initial onset, with recurrent seizures and memory deficits and CSF IgG titer of 1:100. Symptoms were controlled swiftly following the administration of IVIg, and there was no evidence of relapsed teratoma. Figure 1 shows the Kaplan-Meier curves of anti-NMDAR encephalitis patients with and without teratoma.

DISCUSSION

We found that most patients with teratoma recovered slowly. However, favorable clinical outcomes were achieved over long-term follow-up, although mild sequelae may last several years. Immunotherapy was comparably ineffective in patients with teratoma before surgery, but effectiveness improved following removal surgery. Patients with teratoma presented with a more acute onset, more severe neurological symptoms, and higher IgG titer, than those without teratoma. Therefore, earlier and more immunotherapy turns were recommended for these patients.

The prevalence of teratoma in this study was comparably lower than that in previous studies. Titulaer et al. reported a prevalence of 211/577 patients, who were predominantly Asian and African-American (2). On the other hand, Xu et al. reported a prevalence of 42/143 women patients in a Chinese cohort (13). In our study, the prevalence of teratoma was 21/192 patients and was higher in younger individuals. This is consistent with the findings of Titulaer et al. (2) in which teratoma primarily affects individuals aged between 12 and 45 years, recommending more comprehensive inspections for teratoma in female youth. Anti-NMDAR encephalitis triggered by extra-ovarian teratoma, especially mediastinum teratoma, was detected in 2/21 patients with teratoma in our cohort. Overlooked extra-ovarian teratoma may result in delayed diagnosis in some cases (14). In addition, the teratoma cohort presented with more severe neurological sequelae, with greater disturbance of consciousness and central hypoventilation, and higher anti-NMDAR antibody titer in the CSF, which is similar to the report by Gresa-Arribas et al. (15). Accordingly, wider use of ventilators and intensive care has also been reported in this patients group (16). MRI
TABLE 3 | Management and outcomes of patients with teratoma.

| No. | Intravenous immunoglobulin turns | Intravenous methylprednisolone turns | Second-line immunotherapy | Duration from onset to immunotherapy (days) | Duration from onset to removal surgery (days) | mRS score at surgery | mRS score at final follow-up |
|-----|---------------------------------|-------------------------------------|---------------------------|---------------------------------------------|-----------------------------------------------|---------------------|----------------------------|
| Case 1 | 1 | 1 | rituximab | 15 | 165 | 2 | 0 |
| Case 2 | 2 | 1 | - | 20 | 98 | 3 | 1 |
| Case 3 | 2 | - | - | 7 | 87 | 5 | 6 |
| Case 4 | 3 | 1 | - | 7 | 50 | 5 | 2 |
| Case 5 | 1 | - | - | 21 | 272 | 0 | 0 |
| Case 6 | 2 | 1 | - | 10 | 58 | 5 | 0 |
| Case 7 | 3 | 3 | - | 15 | 221 | 0 | 0 |
| Case 8 | 1 | - | - | 20 | 27 | 5 | 1 |
| Case 9 | 1 | 3 | - | 15 | 39 | 4 | 0 |
| Case 10 | 2 | - | - | 2 | 23 | 5 | 0 |
| Case 11 | 3 | 1 | - | 14 | 42 | 5 | 2 |
| Case 12 | 2 | - | - | 20 | 38 | 5 | 0 |
| Case 13 | 1 | 1 | - | 21 | 34 | 4 | 0 |
| Case 14 | 1 | - | - | 22 | 15 | 4 | 2 |
| Case 15 | 2 | 1 | - | 10 | 19 | 4 | 0 |
| Case 16 | 4 | 1 | rituximab | 20 | 125 | 5 | 1 |
| Case 17 | 1 | 1 | cyclophosphamide | 5 | 32 | 4 | 1 |
| Case 18 | 1 | 1 | - | 10 | 27 | 3 | 0 |
| Case 19 | 2 | 2 | rituximab | 35 | 58 | 5 | 6 |
| Case 20 | 2 | - | - | 20 | 47 | 5 | 1 |
| Case 21 | 1 | 2 | - | 7 | 22 | 5 | 1 |

TABLE 4 | Management and outcomes of patients with and without teratoma.

| | Total, n (%) | With teratoma, n (%) | Without teratoma, n (%) | P-values |
|-----------------|-----------------|---------------------|-------------------------|----------|
| Intravenous immunoglobulin | 172 (89.6) | 21 (100) | 151 (88.3) | 0.136⁴ |
| Intravenous methylprednisolone | 122 (63.5) | 14 (66.7) | 108 (63.2) | 0.940⁴ |
| Second-line immunotherapy | 16 (8.3) | 4 (19) | 12 (7) | 0.143⁴ |
| Intravenous first-line immunotherapy turns (median, IQR) | 2 (1–5) | 2 (1–4) | 2 (1–5) | 0.013⁺ |
| mRS score at final follow up | 0 (0–1) | 1 (0–1) | 0 (0–1) | 0.864⁺ |
| Death | 13 (6.8) | 2 (9.5) | 11 (6.4) | 0.943⁴ |
| Relapse | 36 (19.8) | 1 (4.8) | 37 (21.8) | 0.123⁺ |

⁴ chi-squared or Fisher’s exact tests.
⁺ Wilcoxon’s test.

and EEG during the acute phase showed non-specific changes, with limited significance for diagnoses. However, the evaluation using positron emission tomography was recommended in several cases.

Immunotherapy is a crucial element of autoimmune encephalitis treatment. The combination of steroids, intravenous immunoglobulins, and plasma exchange is recommended, and second-line therapy should be administered as soon as possible if first-line therapy is unsuccessful (17). In our study, patients with teratoma responded more poorly to immunotherapy and required more turns of immunotherapy than patients without teratoma. Persistent germinal center response in teratoma can produce NR1-IgG continuously (18). Single immunotherapy has a limited effect in patients with teratoma. However, a high proportion of patients with inadequate response to immunotherapy has been found to improve, following a surgery as reflected in the control of seizures and increased consciousness level. Dalmau et al. observed 105 anti-NMDAR encephalitis patients and reported an 80% response rate to first-line immunotherapy plus surgery in patients with teratoma, whereas the response rate in patients without teratoma was 48% (19). Improvement can be dramatic in some patients, and can even occur within a few days of surgery (20).
Surgery during the acute phase is strongly recommended for a good long-term prognosis. Lee et al. suggest that delayed surgery is associated with poor improvement over time (21). Moreover, Dalmau et al. reported that patients who do not undergo surgery have a higher mortality rate (20). Furthermore, a previous study found that patients who undergo tumor removal within 4 months have milder neurological deficits than those who undergo a delayed surgery (22). Although the safety of undergoing surgery during the acute phase is a significant concern, consistent with a previous study (16), there were no surgical complications during the perioperative period in our cohort. Two of our patients died because of multiple organ failure due to anti-NMDAR encephalitis; however, there was no evidence to indicate that surgery hastened death in these patients.

The detection of teratoma during the early phase is important for medical management. CT and MRI have higher sensitivity than ultrasound for teratoma screening and thus are recommended for patients with anti-NMDAR encephalitis (23). However, patients with anti-NMDAR encephalitis have smaller teratoma with fewer teeth, less calcification, and a smaller fat-occupied space, which makes the detection of teratoma challenging (24). Indeed, Lee et al. reported that diagnosis of teratoma was missed in 26.1% of patients during initial pelvis CT, even when combined with MRI (21). Thus, continual reassessment for teratoma in patients who show no significant improvement with immunotherapy or those who relapse repeatedly is recommended. Although delayed surgery is criticized by many (21), our study indicated that patients can benefit from surgery, even with a delay of over 6 months.

Patients with anti-NMDAR encephalitis along with teratoma have benign prognoses, with a low relapse rate and mild sequelae. The teratoma group had long-term prognoses similar to patients without teratoma in terms of relapse, mortality, and mRS score, regardless of more dreadful onset. However, a lower relapse rate in patients with teratoma has been reported previously (16). One study reported that relapsed or residual teratoma can induce relapse (25), although we found no evidence of relapsed teratoma in patients who relapsed in this study.

Our study has several limitations. Firstly, our sample size of the single-center study was small. A multicenter study would increase the sample size and reduce selection bias. Secondly, the evaluation of prognoses during the post-surgical follow-up was based primarily on patients’ subjective descriptions, and regular anti-NMDAR antibody tests and cranial MRI were not performed for further analysis.

In conclusion, removal surgery to treat anti-NMDAR encephalitis patients with teratoma is effective. Although anti-NMDAR encephalitis patients with teratoma had more serious medical conditions than patients without teratoma, timely removal surgery enabled favorable long-term outcomes.
Comprehensive assessments are required for early tumor detection and timely management, especially in patients who respond poorly to immunotherapy.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by West China Hospital of Sichuan University Research Ethics Committee. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin.

**REFERENCES**

1. Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, et al. A Clinical Approach to Diagnosis of Autoimmune Encephalitis. *Lancet Neurol.* (2016) 15:391–404. doi: 10.1016/S1474-4422(15)00401-9
2. Titulaer MJ, McCracken L, Gabilondo I, Armanagüe T, Glaser C, Izuzka T, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. *Lancet Neurol.* (2013) 12:157–65. doi: 10.1016/S1474-4422(12)70310-1
3. Dalmaj J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Xai M, et al. Anti-NMDA receptor encephalitis: case series and analysis of the effects of antibodies. *Lancet Neurol.* (2008) 7:1091–8. doi: 10.1016/S1474-4422(08)70224-2
4. Jiang XY, Lei S, Zhang L, Liu X, Lin MT, Blumcke I, et al. Co-expression of NMDA receptor subunits NR1, NR2A, and NR2B in dysplastic neurons of teratomas in patients with paraneoplastic nmda-receptor-encephalitis: a retrospective clinico-pathology study of 159 patients. *Acta Neuropathol Commun.* (2020) 8:130. doi: 10.1186/s40478-020-00999-2
5. Bost C, Chanson E, Picard G, Meyronet D, Mayeur ME, Ducasyn F, et al. Malignant tumors in autoimmune encephalitis with anti-NMDA receptor antibodies. *J Neurol.* (2018) 265:2190–200. doi: 10.1007/s00415-018-9070-0
6. Florance NR, Davis RL, Lam C, Sperka C, Zhou L, Ahmad S, et al. Anti-N-methyl-D-aspartate Receptor (NMDAR) encephalitis in children and adolescents. *Ann Neurol.* (2009) 66:11–8. doi: 10.1002/ana.21756
7. Liu X, Zhang L, Chen C, Gong X, Lin J, An D, et al. Long-term cognitive and neuropsychiatric outcomes in patients with anti-NMDAR encephalitis. *Acta Neurol Scand.* (2019) 140:414–21. doi: 10.1111/ane.13160
8. Zhang L, Lu Y, Xu L, Liu W, Zhang Y, et al. Anti-N-methyl-D-aspartate receptor encephalitis with accompanying ovarian teratoma in female patients from east china: clinical features, treatment, and prognostic outcomes. Seizure. (2020) 75:55–62. doi: 10.1016/j.seizure.2019.12.016
9. Wang R, Lai XH, Liu X, Li YJ, Chen C, Li C, et al. Brain magnetic resonance-imaging findings of anti-N-methyl-D-aspartate receptor encephalitis: a cohort follow-up study in Chinese patients. *J Neurol.* (2018) 265:362–9. doi: 10.1007/s00415-017-8707-5
10. Liu X, Yan B, Wang R, Li C, Chen C, Zhou D, et al. Seizure outcomes in patients with anti-NMDAR encephalitis: a follow-up study. *Epilepsia.* (2017) 58:2104–11. doi: 10.1111/epi.13929
11. Gong X, Chen C, Liu X, Lin J, Li A, Guo K, et al. Long-term functional outcomes and relapse of anti-NMDA receptor encephalitis: a cohort study in Western China. *Neuroreport Neuroimmunflam.* (2021) 8:e958. doi: 10.1212/NXI.00000000000009598
12. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. *Stroke.* (1988) 19:604–7. doi: 10.1161/01.STR.19.5.604
13. Xu X, Lu Q, Huang Y, Fan S, Zhou L, Yuan J, et al. Anti-NMDAR encephalitis: a single-center, longitudinal study in China. *Neuro Immunomun Neuroinflamm.* (2019) 7:e633. doi: 10.1212/NXI.0000000000000663
14. Kümpfel T, Gerdes LA, Heck C, Prüss H. Delayed diagnosis of extravascular teratoma in relapsing anti-NMDA receptor encephalitis. *Neuro Immunomun Neuroinflamm.* (2016) 3:e250. doi: 10.1212/NXI.0000000000000250
15. Gresa-Aribas N, Titulaer MJ, Torrents A. Antibody Titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. *Lancet Neurol.* (2014) 13:167–77. doi: 10.1016/S1474-4422(13)70282-5
16. Dai Y, Zhang J, Ren H, Zhou X, Chen J, Cui L, et al. Surgical outcomes in patients with anti-N-methyl-D-aspartate receptor encephalitis with ovarian teratoma. *Am J Obstet Gynecol.* (2019) 221:485.e1–10. doi: 10.1016/j.ajog.2019.05.026
17. Dalmaj J, Armanagüe T, Planagumà J, Radosovic M, Mannara F, Leypoldt F, et al. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models. *Lancet Neurol.* (2019) 18:1045–57. doi: 10.1016/S1474-4422(19)30244-3
18. Makuch M, Wilson R, Al-Diwany A, Varley J, Kienzler A-K, Taylor J, et al. N-methyl-D-aspartate receptor antibody production from germinal center reactions: therapeutic implications. *Ann Neurol.* (2018) 83:553–61. doi: 10.1002/ana.25173
19. Dalmaj J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. *Lancet Neurol.* (2011) 10:63–74. doi: 10.1016/S1474-4422(10)70233-2
20. Dalmaj J, Tüzün E, Wu HY, Masjuan J, Rossi JE, Voloschin A, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. *Ann Neurol.* (2007) 61:25–36. doi: 10.1002/ana.21050
21. Lee WJ, Lee ST, Shin YW, Lee HS, Shin HR, Kim DY, et al. Teratoma removal, steroid, IVIG, rituximab and tocilizumab (T-SIRT) in anti-NMDAR encephalitis. *Neurotherapeutics.* (2021) 18:474–87. doi: 10.1007/s13311-020-00921-7
22. Sommerling C, Santens P. Anti-N-methyl-D-aspartate (anti-NMDA) receptor antibody encephalitis in a male adolescent with a large mediastinal teratoma. *J Child Neurol.* (2014) 29:688–90. doi: 10.1177/0883073813520499
23. Saba L, Guerrier S, Sulcis R, Virgilio B, Melis G, Mallarini G. Mature and immature ovarian teratomas: CT, US and MR imaging characteristics. *Eur J Radiol.* (2009) 72:454–63. doi: 10.1016/j.ejrad.2009.07.044
24. Kawaguchi M, Kato H, Noda Y, Suizui N, Miyazaki T, Furui T, et al. CT and MRI Characteristics of ovarian mature teratoma in patients with anti-N-methyl-D-aspartate receptor encephalitis. *Diagn Interv Imaging.* (2021) 102:447–53. doi: 10.1016/j.diii.2021.02.010
25. Uchida Y, Kato D, Yamashita Y, Ozaki Y, Matsukawa N, et al. Failure to improve after ovarian resection could be a marker of recurrent ovarian

**AUTHOR CONTRIBUTIONS**

HZ: drafting of the manuscript for content, analysis and interpretation of data. WX and WL: revision of the manuscript for content. XL: major role in the acquisition of data. DZ and XW: study concept, design, and revision of the manuscript for content. All authors contributed to the article and approved the submitted version.

**FUNDING**

This work was supported by grants from the National Natural Science Foundation of China (Grant Nos. 81871017 and 81901320), the Chengdu Science and Technology Bureau (2021-YF05-00846-SN), and Chengdu Science and Technology Bureau (2019-YF09-00215-SN).
teratoma in anti-NMDAR encephalitis: a case report. *Neuropsychiatr Dis Treat.* (2018) 14:339–42. doi: 10.2147/NDT.S156603

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Zhang, Xiong, Liu, Liu, Zhou and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.